Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis

• Published in: Expert review of clinical pharmacology Vol. 14; no. 1; p. 67
• Main Authors: Williams, Kyle A, Roh, Youkyung S, Brown, Isabelle, Sutaria, Nishadh, Bakhshi, Pegah, Choi, Justin, Gabriel, Sylvie, Chavda, Rajeev, Kwatra, Shawn G
• Format: Journal Article
• Language: English
• Published: England 02.01.2021
• Subjects: Animals; Biomarkers - metabolism; Chronic Disease; Humans; Prurigo - diagnosis; Prurigo - drug therapy; Prurigo - physiopathology; Pruritus - etiology; Quality of Life; pruritus; symptoms; epidemiology; itch; Prurigo nodularis; comorbidities; physical exam; clinical features
• ISSN: 1751-2441
• DOI: 10.1080/17512433.2021.1852080

: Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules distributed on the trunk and extensor surfaces of the extremities. PN has a profoundly negative impact on sleep and quality of life in patients with PN. There are currently no U.S. Food and Drug Administration-approved agents and patients are often recalcitrant to current therapies, highlighting the importance of further research into this severely debilitating condition. : A PubMed search was conducted to find available literature on the pathophysiology and clinical management of PN. In this review article, we discuss the current understanding of the pathophysiology, recommended diagnostic approach, and treatment options available for PN. : PN is an extremely difficult condition to treat, because there is a lack of effective therapies available due to our limited understanding of its pathophysiology. Currently, available treatment options are often multimodal due to the intersection of neuroimmune etiologic factors in the pathogenesis of PN. Fortunately, as our knowledge of PN expands, novel treatments targeting specific molecular biomarkers of PN are emerging, providing hope to this long-suffering patient population.